Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIZ985 alone and with spartalizumab in advanced solid tumors
NCT02452268Phase 1Terminated
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of NIZ985 in solid tumor (2 arms), sponsored by Novartis. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started May 2017; status: terminated.
02
Drugs
NIZ985
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02452268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452268.